Potent repression of C-reactive protein (CRP) expression by the JAK1/2 inhibitor ruxolitinib in inflammatory human hepatocytes.

Marie Febvre-JamesValérie LecureurOlivier Fardel

Published in: Inflammation research : official journal of the European Histamine Research Society ... [et al.] (2019)

Ruxolitinib can potently repress induction of CRP in inflammatory human hepatocytes, most likely through targeting the IL6/JAK/STAT signalling cascade. Hepatic production of acute-phase proteins during liver inflammation may, therefore, constitute a target for ruxolitinib.

Keyphrases

endothelial cells
oxidative stress
poor prognosis
pluripotent stem cells
liver injury
cancer therapy
long non coding rna